Business Context and Reporting Period
This Form 8-K Current Report was filed by GRI Bio, Inc. on June 18, 2026. The filing reports a material event under Item 8.01 (Other Events) regarding a regulatory milestone for the Company's drug candidate.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory announcement and does not contain financial statements or performance data.
Material Changes
On June 18, 2026, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to the Company's candidate, GRI-0621, for the treatment of idiopathic pulmonary fibrosis. This designation is a significant regulatory development but does not represent a change in financial performance metrics within this document.
Guidance, Outlook, and Risks
The filing incorporates a press release (Exhibit 99.1) detailing the FDA designation. No specific financial guidance, forward-looking projections, or discussion of risks and contingencies is included in the text of this 8-K. The Company is identified as an Emerging Growth Company.
Investor Verification Checklist
- Verify the specific benefits of Orphan Drug Designation for GRI-0621 (e.g., market exclusivity, tax credits) by reviewing the attached press release (Exhibit 99.1).
- Confirm the current clinical development stage of GRI-0621 for idiopathic pulmonary fibrosis.
- Review the Company's most recent 10-Q or 10-K filing for up-to-date financial position and cash runway, as this 8-K contains no financial data.
- Monitor subsequent filings for any updates on the regulatory timeline or clinical trial plans following this designation.